Common genetic variants in the chromogranin a promoter alter autonomic activity and blood pressure

Kidney International

Volumn 74, Issue 1, 2008, Pages 115-125

  Chen, Y ^a,e   Rao, F ^a   Rodriguez Flores, J L ^a   Mahapatra, N R ^a,f   Mahata, M ^a   Wen, G ^a   Salem, R M ^a   Shih, P A B ^a   Das, M ^a   Schork, N J ^a   Ziegler, M G ^a   Hamilton, B A ^a   Mahata, S K ^a,b,d   O'Connor, D T ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PEKING UNIVERSITY FIRST HOSPITAL   (China)

^f INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

Chromaffin; Hypertension; Stress

Indexed keywords

CHROMOGRANIN A; DNA;

ANIMAL CELL; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE REGULATION; CATECHOLAMINE RELEASE; CHGA GENE; COLD STRESS; CONTROLLED STUDY; GENE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HAP A GENE; HAP B GENE; HAPLOTYPE; HETEROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; RAT; SECRETORY VESICLE; TRANSCRIPTION REGULATION;

EID: 45249084746     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.113     Document Type: Article

References (61)

1. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348: 1134-1149.
2. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992; 49: 497-528.
3. Takiyyuddin MA, Cervenka JH, Hsiao RJ et al. Chromogranin A. Storage and release in hypertension. Hypertension 1990; 15: 237-246.
4. Kim T, Tao-Cheng JH, Eiden LE et al. Chromogranin A, an 'on/off' switch controlling dense-core secretory granule biogenesis. Cell 2001; 106: 499-509.
5. Cadman PE, Rao F, Mahata SK et al. Studies of the dysglycemic peptide, pancreastatin, using a human forearm model. Ann N Y Acad Sci 2002; 971: 528-529.
6. Tatemoto K, Efendic S, Mutt V et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986; 324: 476-478.
7. Strub JM, Goumon Y, Lugardon K et al. Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules. J Biol Chem 1996; 271: 28533-28540.
8. Aardal S, Helle KB, Elsayed S et al. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 1993; 5: 405-412.
9. Mahata SK, Mahata M, Parmer RJ et al. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999; 274: 2920-2928.
10. Mahata SK, O'Connor DT, Mahata M et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-1633.
11. Hsiao RJ, Parmer RJ, Takiyyuddin MA et al. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991; 70: 33-45.
12. O'Connor DT. Plasma chromogranin A. Initial studies in human hypertension. Hypertension 1985; 7: I76-I79.
13. Takiyyuddin MA, Cervenka JH, Sullivan PA et al. Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 1990; 81: 185-195.
14. Takiyyuddin MA, Parmer RJ, Kailasam MT et al. Chromogranin A in human hypertension. Influence of heredity. Hypertension 1995; 26: 213-220.
15. O'Connor DT, Takiyyuddin MA, Printz MP et al. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 1999; 8: 285-295.
16. O'Connor DT, Kailasam MT, Kennedy BP et al. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002; 20: 1335-1345.
17. Dimsdale JE, O'Connor DT, Ziegler M et al. Chromogranin A correlates with norepinephrine release rate. Life Sci 1992; 51: 519-525.
18. Mahapatra NR, O'Connor DT, Vaingankar SM et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115: 1942-1952.
19. Wen G, Mahata SK, Cadman P et al. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 2004; 74: 197-207.
20. Barrett JC, Fry B, Maller J et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
21. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504.
22. Zhang L, Rao F, Wessel J et al. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics 2004; 19: 277-291.
23. Halperin E, Eskin E. Haplotype reconstruction from genotype data using imperfect phylogeny. Bioinformatics 2004; 20: 1842-1849.
24. Comings DE, MacMurray JP. Molecular heterosis: a review. Mol Genet Metab 2000; 71: 19-31.
25. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769.
26. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003; 41: 207-210.
27. Sandelin A, Wasserman WW, Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res 2004; 32: W249-W252.
28. Cooney AJ, Lee CT, Lin SC et al. Physiological function of the orphans GCNF and COUP-TF. Trends Endocrinol Metab 2001; 12: 247-251.
29. Gaetano C, Manni I, Bossi G et al. Retinoic acid and cAMP differentially regulate human chromogranin A promoter activity during differentiation of neuroblastoma cells. Eur J Cancer 1995; 31A: 447-452.
30. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 265: 2037-2048.
31. Lillie EO, O'Connor DT. Early phenotypic changes in hypertension: a role for the autonomic nervous system and heredity. Hypertension 2006; 47: 331-333.
32. Kasagi F, Akahoshi M, Shimaoka K. Relation between cold pressor test and development of hypertension based on 28-year follow-up. Hypertension 1995; 25: 71-76.
33. Menkes MS, Matthews KA, Krantz DS et al. Cardiovascular reactivity to the cold pressor test as a predictor of hypertension. Hypertension 1989; 14: 524-530.
34. Schneider GM, Jacobs DW, Gevirtz RN et al. Cardiovascular haemodynamic response to repeated mental stress in normotensive subjects at genetic risk of hypertension: evidence of enhanced reactivity, blunted adaptation, and delayed recovery. J Hum Hypertens 2003; 17: 829-840.
35. Snieder H, Harshfield GA, Barbeau P et al. Dissecting the genetic architecture of the cardiovascular and renal stress response. Biol Psychol 2002; 61: 73-95.
36. Treiber FA, Kamarck T, Schneiderman N et al. Cardiovascular reactivity and development of preclinical and clinical disease states. Psychosom Med 2003; 65: 46-62.
37. O'Connor DT, Insel PA, Ziegler MG et al. Heredity and the autonomic nervous system in human hypertension. Curr Hypertens Rep 2000; 2: 16-22.
38. Seasholtz TM, Wessel J, Rao F et al. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension 2006; 47: 937-947.
39. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976; 73: 2424-2428.
40. Tang K, Wu H, Mahata SK et al. Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of cytosolic calcium entry and protein kinase C. J Clin Invest 1997; 100: 1180-1192.
41. Tang K, Wu H, Mahata SK et al. A crucial role for the mitogen-activated protein kinase pathway in nicotinic cholinergic signaling to secretory protein transcription in pheochromocytoma cells. Mol Pharmacol 1998; 54: 59-69.
42. Tang K, Wu H, Mahata SK et al. Stimulus-transcription coupling in pheochromocytoma cells. Promoter region-specific activation of chromogranin a biosynthesis. J Biol Chem 1996; 271: 28382-28390.
43. Taupenot L, Mahata M, Mahata SK et al. Time-dependent effects of the neuropeptide PACAP on catecholamine secretion: stimulation and desensitization. Hypertension 1999; 34: 1152-1162.
44. Taupenot L, Mahata SK, Wu H et al. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP). J Clin Invest 1998; 101: 863-876.
45. Wu H, Mahata SK, Mahata M et al. A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A. J Clin Invest 1995; 96: 568-578.
46. Wu H, Rozansky DJ, Webster NJ et al. Cell type-specific gene expression in the neuroendocrine system. A neuroendocrine-specific regulatory element in the promoter of chromogranin A, a ubiquitous secretory granule core protein. J Clin Invest 1994; 94: 118-129.
47. Pardell H, Rodicio JL. High blood pressure, smoking and cardiovascular risk. J Hypertens 2005; 23: 219-221.
48. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D et al. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 1992; 267: 15849-15860.
49. Leng X, Cooney AJ, Tsai SY et al. Molecular mechanisms of COUP-TF-mediated transcriptional repression: evidence for transrepression and active repression. Mol Cell Biol 1996; 16: 2332-2340.
50. Pereira FA, Tsai MJ, Tsai SY. COUP-TF orphan nuclear receptors in development and differentiation. Cell Mol Life Sci 2000; 57: 1388-1398.
51. Cooney AJ, Tsai SY, O'Malley BW et al. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTCA response elements, allowing COUP-TF to repress hormonal induction of the vitamin D3, thyroid hormone, and retinoic acid receptors. Mol Cell Biol 1992; 12: 4153-4163.
52. Tsai SY, Tsai MJ. Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. Endocr Rev 1997; 18: 229-240.
53. Herrmann V, Buscher R, Go MM et al. Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens 2000; 13: 1021-1026.
54. Buetow KH, Edmonson M, MacDonald R et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 2001; 98: 581-584.
55. Ahmadian A, Ehn M, Hober S. Pyrosequencing: history, biochemistry and future. Clin Chim Acta 2006; 363: 83-94.
56. Greenwood TA, Rao F, Stridsberg M et al. Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. Physiol Genomics 2006; 25: 470-479.
57. Wessel J, Moratorio G, Rao F et al. C-reactive protein, an 'intermediate phenotype' for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrenergic pathway loci. J Hypertens 2007; 25: 329-343.
58. Dickerson IM, Mains RE. Cell-type specific posttranslational processing of peptides by different pituitary cell lines. Endocrinology 1990; 127: 133-140.
59. Rozansky DJ, Wu H, Tang K et al. Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest 1994; 94: 2357-2368.
60. Kang S, Spann NJ, Hui TY et al. ARP-1/COUP-TF II determines hepatoma phenotype by acting as both a transcriptional repressor of microsomal triglyceride transfer protein and an inducer of CYP7A1. J Biol Chem 2003; 278: 30478-30486.
61. Do KA, Broom BM, Kuhnert P et al. Genetic analysis of the age at menopause by using estimating equations and Bayesian random effects models. Stat Med 2000; 19: 1217-1235.